cCAM Biotherapeutics Receives Phase I FDA Approval

January 7, 2015 | An Israeli biopharmaceutical company, cCAM Biotherapeutics, announced that it received Food & Drug Administration approval to begin a Phase I trial for CM-24. CM-24 is a antibody for the treatment of various types of cancers. cCAM was founded in 2010 and focuses on the discovery and development of novel immunotherapies to treat cancer. The CM-24 antibody was discovered by Dr. Gal Markel, Head of Research in the Ella Institute of Melanoma at Sheba Academic Medical Center.